Published:July 20, 2020DOI: https://doi.org/10.1016/S0140-6736(20)31605-6
___________
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2
This is the study that you likely heard about early in the week with the promising results from the Astra Zenica Phase II vaccine trial in the UK. Promising results indeed! Not only did the vaccine tested form antibodies at several doses, it also generated cell mediated immunity (called killer T cells).
